DUBLIN, Ireland — Keenova Therapeutics plc announced the publication of a new manuscript presenting real-world evidence on treatment patterns for patients with plantar fibromatosis. The peer‑reviewed article appears in The Journal of Foot and Ankle Surgery, available here.
Why It Matters
Plantar fibromatosis is a progressive condition with no FDA-approved nonsurgical treatment options. With no official treatment guidelines available, Keenova and its clinical partners are working to better understand how healthcare providers manage the condition in real‑world practice. Keenova is also investigating collagenase clostridium histolyticum (CCH) as a potential nonsurgical therapy. CCH is not approved for treating plantar fibromatosis.
CSO Perspective
“We believe patients with this rare condition deserve more treatment options, especially those seeking alternatives to surgery,” said Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer at Keenova. “That’s why we are actively investigating a nonsurgical approach in our Phase 3 clinical trial, with the goal of supporting patient care and helping to improve quality of life for the people who need it most.”
What We Learned
Findings from the manuscript show:
- Plantar fibromatosis is rare, but it appears consistently in real‑world data, indicating that it is regularly diagnosed and treated despite its low overall prevalence.
- Most patients receive treatments such as injectable corticosteroids, oral corticosteroids, and physical/occupational therapy.
- Although surgery is infrequent, conservative treatments often continue after surgery, which may suggest disease recurrence or persistent symptoms.
- These patterns indicate a need for more research to understand long‑term outcomes and identify effective treatments for people with refractory plantar fibromatosis.
Phase 3 Status
- Keenova’s Phase 3 clinical trial evaluating CCH for plantar fibromatosis is currently underway.
Manuscript Details
- Title: Real-World Treatment Patterns Among Newly Diagnosed Patients With Plantar Fibromatosis in the United States
- Authors: Jill Davis, MS; Aimee Near, MPH; Jenny Tse, MS; Riddhi Doshi, PhD, MBBS, MPH; Elizabeth Wang, MS; Luis Ortega, MD; David Hurley, MD; David G. Armstrong, MD, PhD, MS
About Plantar Fibromatosis
Plantar fibromatosis or Ledderhose disease is a hyperproliferative fibrous tissue disorder resulting in the formation of collagen nodules along the plantar fascia, the thick connective tissue that supports the arch of the foot, which is often painful. There is no cure for plantar fibromatosis. Symptom management options include custom insoles (orthotics), topical treatments, over-the-counter pain and anti-inflammatory medications, radiation therapy and steroid injections, and ultimately, surgery may be required to remove the nodules.
About Keenova
Keenova Therapeutics is a leading global developer and manufacturer of branded therapeutics that strives to help patients with rare or unaddressed conditions live happier and healthier lives.
The Company’s diversified brands portfolio is focused across a wide range of therapeutic areas of significant unmet need, including endocrinology, gastroenterology, hepatology, immunology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology and urology. Globally headquartered in Dublin, Ireland, Keenova benefits from a strong U.S. manufacturing footprint with facilities in Louisiana, New Jersey, New York, Pennsylvania and Wisconsin. To learn more, please visit www.keenova.com.
Keenova uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (“SEC”) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
Media Contact
Investors Contact